Revance Therapeutics, Inc. (RVNC) Financials

RVNC Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 478.5 million 630.1 million
2023-09-30 532.5 million 638.7 million
2023-06-30 597.5 million 570.7 million
2023-03-31 547.8 million 574.5 million

RVNC Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -44.5 million 8.8 million
2023-09-30 -55.5 million 10.3 million
2023-06-30 -53.1 million 15.6 million
2023-03-31 -70.4 million 13.1 million

RVNC Net Income

No data available :(

RVNC Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 254.5 million - 49.3 million
2023-09-30 300.2 million - 59.5 million
2023-06-30 319.7 million 380.3 million 52.0 million
2023-03-31 273.9 million 379.9 million 55.9 million

RVNC Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 90.1 million
2023-09-30 86.6 million
2023-06-30 83.7 million
2023-03-31 81.1 million

RVNC Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 1.8 million 19.7 million -169.1 million 253.4 million
2023-09-30 4.5 million 13.1 million 67.7 million -
2023-06-30 266000 22.8 million 76.3 million 1.0 million
2023-03-31 870000 23.2 million 63.9 million 2.1 million

RVNC Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 69.8 million 18.9 million
2023-09-30 56.8 million 19.4 million
2023-06-30 58.1 million 21.3 million
2023-03-31 49.3 million 16.2 million

RVNC

Price: $3.80

52 week price:
3.29
37.98

Earnings Per Share: -3.83 USD

P/E Ratio: -1.12

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 728800

Ebitda: -30.2 million

Market Capitalization: 413.7 million

Links: